U.S. Markets closed
  • S&P 500

    4,400.64
    -0.82 (-0.02%)
     
  • Dow 30

    34,930.93
    -127.59 (-0.36%)
     
  • Nasdaq

    14,762.58
    +102.01 (+0.70%)
     
  • Russell 2000

    2,224.96
    +33.12 (+1.51%)
     
  • Crude Oil

    72.37
    +0.72 (+1.00%)
     
  • Gold

    1,806.00
    +6.20 (+0.34%)
     
  • Silver

    25.00
    +0.35 (+1.40%)
     
  • EUR/USD

    1.1847
    +0.0021 (+0.1777%)
     
  • 10-Yr Bond

    1.2610
    +0.0270 (+2.19%)
     
  • Vix

    18.31
    -1.05 (-5.42%)
     
  • GBP/USD

    1.3909
    +0.0030 (+0.2156%)
     
  • USD/JPY

    109.9200
    +0.1530 (+0.1394%)
     
  • BTC-USD

    39,894.10
    +1,612.58 (+4.21%)
     
  • CMC Crypto 200

    938.33
    +8.40 (+0.90%)
     
  • FTSE 100

    7,016.63
    +20.55 (+0.29%)
     
  • Nikkei 225

    27,581.66
    -388.56 (-1.39%)
     

Protalix Shares Hits 52-Week Low After Adverse Event Reported In Fabry Disease Trial With PRX-102

·1 min read
  • Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Farmaceutici S.p.A. have provided an update on the clinical development of pegunigalsidase alfa (PRX–102) for the proposed treatment of Fabry disease.

  • PRX–102 is currently being studied in Phase 3 BALANCE trial evaluating the safety and efficacy of 1 mg/kg of PRX–102 dosed every two weeks compared to agalsidase beta (Fabrazyme).

  • The primary endpoint of the study is the comparison of mean annualized changes (slope) of the eGFR (CKD-EPI) after completion of at least 12 months of treatment between the two treatment arms.

  • The initial top-line results show that the lower boundary of the confidence interval for the mean difference between the two treatments was below the non-inferiority margin pre-specified in the Intention to Treat analysis set and above such limit in the Intention to Treat analysis set.

  • At the time of this analysis (n=77), two patients discontinued participation due to treatment-emergent adverse events - one discontinued participation due to a related adverse event. No deaths were registered.

  • Unblinded final data are anticipated in Q2 of 2022 after all remaining patients have completed the 24-month treatment period.

  • Despite reporting safety issues, the company will move forward with marketing application in Europe PRX–102 in Fabry disease.

  • Regarding the regulatory process in the U.S., the companies plan to submit a Type–A meeting request with the FDA to discuss the path for approval of PRX–102.

  • In April, the companies received FDA Complete Response Letter for PRX‑102 for Fabry disease, though no safety concerns were noted in the letter.

  • Price Action: PLX shares are down 13.8% at $2.57 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.